Williams Lewis T

SEC source: 0001104659-26-017176 · tm266755-1_4seq1.xml · derivative · entry 3

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 18,000 shares

Expires 2027-06-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: These stock options are fully vested.

SEC source: 0001104659-26-017176 · tm266755-1_4seq1.xml · nonDerivative · entry 2

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,825

F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $81.47 to $83.12. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001104659-26-017176 · tm266755-1_4seq1.xml · nonDerivative · entry 1

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,825

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-26-001476 · tm262304-5_4seq1.xml · derivative · entry 2

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,762

Underlying: Common Stock · 3,762 shares

Expires 2036-01-02

F2 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

SEC source: 0001104659-26-001476 · tm262304-5_4seq1.xml · nonDerivative · entry 1

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,825

F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date.

SEC source: 0001104659-25-001432 · tm252003-6_4seq1.xml · derivative · entry 2

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,584

Underlying: Common Stock · 6,584 shares

Expires 2035-01-02

F2 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

SEC source: 0001104659-25-001432 · tm252003-6_4seq1.xml · nonDerivative · entry 1

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,130

F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date.

SEC source: 0001104659-24-001494 · tm241954-6_4seq1.xml · derivative · entry 1

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,700

Underlying: Common Stock · 25,700 shares

Expires 2034-01-02

F1 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

SEC source: 0001104659-23-004737 · tm233829-9_4seq1.xml · derivative · entry 1

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-01-15

F1 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following the date of grant.

SEC source: 0001104659-22-065862 · tm2214526-5_4seq1.xml · derivative · entry 1

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-05-26

F1 · derivative.exercise_date: The stock option vests in full on the earlier of (i) May 26, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Issuer through such date.

SEC source: 0001209191-22-008160 · doc4.xml · derivative · entry 3

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 931,228 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: All shares of Series B-1 Preferred Stock, par value $0.001 per share, and Series B-2 Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Series B-1 Preferred Stock and Series B-2 Preferred Stock into Common Stock had no expiration date.

F1 · price: All shares of Series B-1 Preferred Stock, par value $0.001 per share, and Series B-2 Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Series B-1 Preferred Stock and Series B-2 Preferred Stock into Common Stock had no expiration date.

F1 · derivative.exercise_date: All shares of Series B-1 Preferred Stock, par value $0.001 per share, and Series B-2 Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Series B-1 Preferred Stock and Series B-2 Preferred Stock into Common Stock had no expiration date.

F1 · derivative.expiration_date: All shares of Series B-1 Preferred Stock, par value $0.001 per share, and Series B-2 Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Series B-1 Preferred Stock and Series B-2 Preferred Stock into Common Stock had no expiration date.

F2 · ownership.nature: Shares directly held by Quan Venture Fund II, L.P. The general partner of Quan Capital is Quan Venture Partners II, L.L.C. The Reporting Person, a member of the Issuer's board of directors, is a venture partner at Quan Venture Partners II, L.L.C. and, therefore, may be deemed to have a pecuniary interest over these shares. The Reporting Person disclaims beneficial ownership of the shares held of record by Quan Venture Fund II, L.P. except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-008160 · doc4.xml · derivative · entry 2

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,163,886 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: All shares of Series B-1 Preferred Stock, par value $0.001 per share, and Series B-2 Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Series B-1 Preferred Stock and Series B-2 Preferred Stock into Common Stock had no expiration date.

F1 · price: All shares of Series B-1 Preferred Stock, par value $0.001 per share, and Series B-2 Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Series B-1 Preferred Stock and Series B-2 Preferred Stock into Common Stock had no expiration date.

F1 · derivative.exercise_date: All shares of Series B-1 Preferred Stock, par value $0.001 per share, and Series B-2 Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Series B-1 Preferred Stock and Series B-2 Preferred Stock into Common Stock had no expiration date.

F1 · derivative.expiration_date: All shares of Series B-1 Preferred Stock, par value $0.001 per share, and Series B-2 Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Series B-1 Preferred Stock and Series B-2 Preferred Stock into Common Stock had no expiration date.

F2 · ownership.nature: Shares directly held by Quan Venture Fund II, L.P. The general partner of Quan Capital is Quan Venture Partners II, L.L.C. The Reporting Person, a member of the Issuer's board of directors, is a venture partner at Quan Venture Partners II, L.L.C. and, therefore, may be deemed to have a pecuniary interest over these shares. The Reporting Person disclaims beneficial ownership of the shares held of record by Quan Venture Fund II, L.P. except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-008160 · doc4.xml · nonDerivative · entry 1

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,095,114

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: All shares of Series B-1 Preferred Stock, par value $0.001 per share, and Series B-2 Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The right to convert the Series B-1 Preferred Stock and Series B-2 Preferred Stock into Common Stock had no expiration date.

F2 · ownership.nature: Shares directly held by Quan Venture Fund II, L.P. The general partner of Quan Capital is Quan Venture Partners II, L.L.C. The Reporting Person, a member of the Issuer's board of directors, is a venture partner at Quan Venture Partners II, L.L.C. and, therefore, may be deemed to have a pecuniary interest over these shares. The Reporting Person disclaims beneficial ownership of the shares held of record by Quan Venture Fund II, L.P. except to the extent of his pecuniary interest therein.

SEC source: 0001209191-21-036680 · doc4.xml · derivative · entry 1

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2031-05-26

F1 · derivative.exercise_date: The shares subject to this option shall vest at the earlier of (i) May 27, 2022, or (ii) the date of the 2022 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan).

SEC source: 0001209191-21-032406 · doc4.xml · derivative · entry 1

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2031-05-10

F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning June 11, 2021 until the option is fully vested on May 11, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-20-033032 · doc4.xml · derivative · entry 1

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-05-27

F1 · derivative.exercise_date: The shares subject to this option shall vest at the earlier of (i) May 28, 2021, or (ii) the date of the 2021 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan).

SEC source: 0001209191-20-027694 · doc4.xml · derivative · entry 1

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2030-05-05

F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning June 5, 2020 until the option is fully vested on May 5, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0000899243-19-025571 · doc4.xml · derivative · entry 1

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2029-10-09

F1 · derivative.exercise_date: The options will vest as to 1/3 of the total number of shares underlying the options on each of October 10, 2020, October 10, 2021 and October 10, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-19-048076 · doc4.xml · nonDerivative · entry 1

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 455,336

SEC source: 0001209191-19-036513 · doc4.xml · derivative · entry 1

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2029-06-09

F1 · derivative.exercise_date: This option will vest in its entirety on the earlier to occur of (i) June 10, 2020 or (ii) the day before the 2020 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the "Company"), subject to the reporting person's continued service to the Company through such vest date.

SEC source: 0001209191-19-036211 · doc4.xml · derivative · entry 1

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2029-06-06

F1 · derivative.exercise_date: The shares subject to this option shall vest at the earlier of (i) June 7, 2020, or (ii) the date of the 2020 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan).

SEC source: 0001209191-19-014250 · doc4.xml · nonDerivative · entry 1

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 461,360

SEC source: 0001209191-19-014685 · doc4a.xml · derivative · entry 2

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,400

Underlying: Common Stock · 6,400 shares

Expires 2029-02-24

F2 · shares: This amendment is being filed to reflect the grant to the reporting person of (i) 1,000 shares of restricted common stock of the Company and (ii) 6,400 options to purchase shares of common stock of the Company, each of which was inadvertently omitted from the reporting person's original Form 4 filed with the Securities and Exchange Commission (the "SEC") on February 27, 2019.

F4 · derivative.exercise_date: The shares underlying the option vest at a rate of one forty-eighth (1/48) per month following February 25, 2019, provided the reporting person provides services to the Company through each such date.

SEC source: 0001209191-19-014685 · doc4a.xml · nonDerivative · entry 1

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 462,360

F1 · shares: Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of February 25, 2020, 2021 and 2022, provided the reporting person provides services to Five Prime Therapeutics, Inc. (the "Company") through each such date.

F2 · shares: This amendment is being filed to reflect the grant to the reporting person of (i) 1,000 shares of restricted common stock of the Company and (ii) 6,400 options to purchase shares of common stock of the Company, each of which was inadvertently omitted from the reporting person's original Form 4 filed with the Securities and Exchange Commission (the "SEC") on February 27, 2019.

F3 · balance_after: Reflects the holdings of the reporting person as of the date of the original Form 4 filed with the SEC on February 27, 2019, taking into account the transaction set forth in such original Form 4 and the transaction set forth in this amendment.

SEC source: 0001209191-19-008141 · doc4.xml · nonDerivative · entry 1

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 462,286

SEC source: 0001209191-18-058417 · doc4.xml · derivative · entry 2

Williams Lewis T · CIK 0001475714 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 91,217 shares

Expires 2019-04-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option is fully vested and immediately exercisable.

SEC source: 0001209191-18-058417 · doc4.xml · nonDerivative · entry 1

Williams Lewis T · CIK 0001475714 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 465,430

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-18-049446 · doc4.xml · nonDerivative · entry 1

Williams Lewis T · CIK 0001475714 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 374,213

SEC source: 0001209191-18-037318 · doc4.xml · derivative · entry 1

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2028-05-28

F1 · derivative.exercise_date: The shares subject to this option shall vest at the earlier on (i) May 29, 2019, or (ii) the date of the 2019 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan).

SEC source: 0001209191-18-014712 · doc4.xml · derivative · entry 2

Williams Lewis T · CIK 0001475714 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2028-02-25

F2 · derivative.exercise_date: The shares underlying the option vest at a rate of one forty-eighth (1/48th) per month following February 26, 2018, provided the reporting person provides services the Company through each such date.

SEC source: 0001209191-18-014712 · doc4.xml · nonDerivative · entry 1

Williams Lewis T · CIK 0001475714 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 381,237

F1 · shares: Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of February 26, 2019, 2020 and 2021, provided the reporting person provides services to Five Prime Therapeutics, Inc. (the "Company") through each such date.

SEC source: 0001209191-18-008075 · doc4.xml · nonDerivative · entry 1

Williams Lewis T · CIK 0001475714 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 376,237

SEC source: 0001209191-17-051801 · doc4.xml · nonDerivative · entry 1

Williams Lewis T · CIK 0001475714 · Director · President, CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 381,958

F1 · balance_after: Includes 600 shares acquired on November 15, 2016 and 431 shares acquired on May 15, 2017 pursuant to Five Prime Therapeutics, Inc.'s 2013 Employee Stock Purchase Plan.

SEC source: 0001209191-17-040261 · doc4.xml · derivative · entry 1

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2027-06-15

F1 · derivative.exercise_date: The shares subject to the option shall vest in 36 equal monthly installments from the vesting commencement date of June 15, 2017.

SEC source: 0001209191-17-017144 · doc4.xml · nonDerivative · entry 1

Williams Lewis T · CIK 0001475714 · Director · President, CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 388,754

SEC source: 0001209191-17-009300 · doc4.xml · derivative · entry 3

Williams Lewis T · CIK 0001475714 · Director · President, CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,250

Underlying: Common Stock · 101,250 shares

Expires 2027-02-06

F2 · derivative.exercise_date: The shares underlying the option vest at a rate of one forty-eighth (1/48th) per month beginning on March 7, 2017, provided the reporting person provides services to Five Prime Therapeutics, Inc. through each such date.

SEC source: 0001209191-17-009300 · doc4.xml · nonDerivative · entry 2

Williams Lewis T · CIK 0001475714 · Director · President, CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 423,286

F1 · shares: Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of February 5, 2018, 2019 and 2020, provided the reporting person provides services to Five Prime Therapeutics, Inc. through each such date.

SEC source: 0001209191-17-001849 · doc4.xml · nonDerivative · entry 1

Williams Lewis T · CIK 0001475714 · Director · President, CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 428,827

SEC source: 0001209191-16-156690 · doc4.xml · derivative · entry 10

Williams Lewis T · CIK 0001475714 · Director · President, CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,159

Underlying: Common Stock · 29,816 shares

Expires 2022-07-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option is fully vested and immediately exercisable.

SEC source: 0001209191-16-156690 · doc4.xml · derivative · entry 9

Williams Lewis T · CIK 0001475714 · Director · President, CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,349

Underlying: Common Stock · 10 shares

Expires 2021-10-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option is fully vested and immediately exercisable.

SEC source: 0001209191-16-156690 · doc4.xml · derivative · entry 8

Williams Lewis T · CIK 0001475714 · Director · President, CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,438

Underlying: Common Stock · 19 shares

Expires 2020-07-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option is fully vested and immediately exercisable.

SEC source: 0001209191-16-156690 · doc4.xml · derivative · entry 7

Williams Lewis T · CIK 0001475714 · Director · President, CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,217

Underlying: Common Stock · 155 shares

Expires 2019-04-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option is fully vested and immediately exercisable.

SEC source: 0001209191-16-156690 · doc4.xml · nonDerivative · entry 6

Williams Lewis T · CIK 0001475714 · Director · President, CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 433,892

F1 · kind: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2016.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.00 to $51.04, inclusive.

SEC source: 0001209191-16-156690 · doc4.xml · nonDerivative · entry 5

Williams Lewis T · CIK 0001475714 · Director · President, CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 434,192

F1 · kind: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2016.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.94, inclusive. The reporting person undertakes to provide to Five Prime Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.

SEC source: 0001209191-16-156690 · doc4.xml · nonDerivative · entry 4

Williams Lewis T · CIK 0001475714 · Director · President, CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 463,892

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-16-156690 · doc4.xml · nonDerivative · entry 3

Williams Lewis T · CIK 0001475714 · Director · President, CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 434,076

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-16-156690 · doc4.xml · nonDerivative · entry 2

Williams Lewis T · CIK 0001475714 · Director · President, CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 434,066

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-16-156690 · doc4.xml · nonDerivative · entry 1

Williams Lewis T · CIK 0001475714 · Director · President, CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 434,047

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-16-141666 · doc4.xml · nonDerivative · entry 1

Williams Lewis T · CIK 0001475714 · Director · President, CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 433,892

SEC source: 0001209191-17-009300 · doc4.xml · nonDerivative · entry 1

Williams Lewis T · CIK 0001475714 · Director · President, CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 406,411